Eribulin Treatment as 1st-line or 2nd-line Chemotherapy for HER2-negative Hormone-resistant Inoperable or Recurrent Metastatic Breast Cancer
Status: COMPLETED
Study type: OBSERVATIONAL
Conditions: Breast Cancer
Interventions: DRUG: Eribulin
Sponsor: Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Collaborators: Kyoto Breast Cancer Research Network